European Society of Endocrinology clinical guideline: Treatment of chronic hypoparathyroidism in adults

European Journal of Endocrinology

Volumn 173, Issue 2, 2015, Pages G1-G20

  Bollerslev, Jens ^a,b   Rejnmark, Lars ^c   Marcocci, Claudio ^d   Shoback, Dolores M ^e   Sitges Serra, Antonio ^f   Van Biesen, Wim ^g   Dekkers, Olaf M ^c,h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HOSPITAL DEL MAR   (Spain)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; CALCIUM SALT; ERGOCALCIFEROL; MAGNESIUM; PHOSPHATE; VITAMIN D;

ARTICLE; BONE DENSITY; BREAST FEEDING; CALCIUM HOMEOSTASIS; CHRONIC DISEASE; CHRONIC HYPOPARATHYROIDISM; CLINICAL EVALUATION; DIET THERAPY; DISEASE CONTROL; ELECTROLYTE BLOOD LEVEL; EUROPE; EUROPEAN SOCIETY OF ENDOCRINOLOGY; EVIDENCE BASED PRACTICE; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HORMONE SUBSTITUTION; HUMAN; HYPOPARATHYROIDISM; KIDNEY DISEASE; MEDICAL DECISION MAKING; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION; ADULT; ENDOCRINOLOGY; MEDICAL SOCIETY; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

ADULT; CHRONIC DISEASE; ENDOCRINOLOGY; HUMANS; HYPOPARATHYROIDISM; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84938875353     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0628     Document Type: Article

References (107)

1. Cusano NE, Rubin MR & Bilezikian JP. Parathyroid hormone therapy for hypoparathyroidism. Best Practice & Research. Clinical Endocrinology & Metabolism 2015 29 47-55. (doi:10.1016/j.beem.2014.09.001)
2. Khan MI, Waguespack SG & Hu MI. Medical management of postsurgical hypoparathyroidism. Endocrine Practice 2011 17 (Suppl 1) 18-25. (doi:10.4158/EP10302.RA)
3. Rejnmark L, Underbjerg L & Sikjaer T. Therapy of hypoparathyroidism by replacement with parathyroid hormone. Scientifica 2014 2014 765629. (doi:10.1155/2014/765629)
4. Shoback D. Clinical practice. Hypoparathyroidism. New England Journal of Medicine 2008 359 391-403. (doi:10.1056/NEJMcp0803050)
5. Puzziello A, Rosato L, Innaro N, Orlando G, Avenia N, Perigli G, Calò PG & De Palma M. Hypocalcemia following thyroid surgery: incidence and risk factors. A longitudinal multicenter study comprising 2,631 patients. Endocrine 2014 47 537-542. (doi:10.1007/s12020-014-0209-y)
6. Betterle C, Garelli S & Presotto F. Diagnosis and classification of autoimmune parathyroid disease. Autoimmunity Reviews 2014 13 417-422. (doi:10.1016/j.autrev.2014.01.044)
7. Lima K, Abrahamsen TG, Wolff AB, Husebye E, Alimohammadi M, Kämpe O & Følling I. Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome. European Journal of Endocrinology 2011 165 345-352. (doi:10.1530/EJE-10-1206)
8. Underbjerg L, Sikjaer T, Mosekilde L & Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. Journal of Bone and Mineral Research 2013 28 2277-2285. (doi:10.1002/jbmr.1979)
9. Underbjerg L, Sikjaer T, Mosekilde L & Rejnmark L. The epidemiology of non-surgical hypoparathyroidism in Denmark: a nationwide case finding study. Journal of Bone and Mineral Research, 2015. In press. (doi:10.1002/jbmr.2501)
10. Powers J, Joy K, Ruscio A & Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. Journal of Bone and Mineral Research 2013 28 2570-2576. (doi:10.1002/jbmr.2004)
11. Lorente-Poch L, Sancho JJ, Munoz-Nova JL, Sanchez-Velazquez P & Sitges-Serra A. Defining the syndromes of parathyroid failure after total thyroidectomy. Gland Surgery 2015 4 82-90.
12. Edafe O, Antakia R, Laskar N, Uttley L & Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. British Journal of Surgery 2014 101 307-320. (doi:10.1002/bjs.9384)
13. Sitges-Serra A, Ruiz S, Girvent M, Manjon H, Duenas JP & Sancho JJ. Outcome of protracted hypoparathyroidism after total thyroidectomy. British Journal of Surgery 2010 97 1687-1695. (doi:10.1002/bjs.7219)
14. Barczynski M, Cichon S & Konturek A. Which criterion of intraoperative iPTH assay is the most accurate in prediction of true serum calcium levels after thyroid surgery? Langenbeck's Archives of Surgery 2007 392 693-698. (doi:10.1007/s00423-007-0165-6)
15. Grodski S & Serpell J. Evidence for the role of perioperative PTH measurement after total thyroidectomy as a predictor of hypocalcemia. World Journal of Surgery 2008 32 1367-1373. (doi:10.1007/s00268-008-9545-5)
16. Lorente-Poch L, Sancho JJ, Ruiz S & Sitges-Serra A. Importance of in situ preservation of parathyroid glands during total thyroidectomy. British Journal of Surgery 2015 102 359-367. (doi:10.1002/bjs.9676)
17. Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W & Allolio B. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. European Journal of Endocrinology 2002 146 215-222. (doi:10.1530/eje.0.1460215)
18. Cusano NE, Rubin MR, McMahon DJ, Irani D, Tulley A, Sliney J Jr & Bilezikian JP. The effect of PTH(1-84) on quality of life in hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 2013 98 2356-2361. (doi:10.1210/jc.2013-1239)
19. Murdoch DL, Forrest G, Davies DL & McInnes GT. A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects. British Journal of Clinical Pharmacology 1993 35 373-378. (doi:10.1111/j.1365-2125. 1993.tb04153.x)
20. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L & Mosekilde L. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. Journal of Bone and Mineral Research 2011 26 2358-2370. (doi:10.1002/jbmr.470)
21. Underbjerg L, Sikjaer T, Mosekilde L & Rejnmark L. Postsurgical hypoparathyroidism - risk of fractures, psychiatric diseases, cancer, cataract, and infections. Journal of Bone and Mineral Research 2014 29 2504-2510. (doi:10.1002/jbmr.2273)
22. Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA & Mannstadt M. Long-term follow-up of patients with hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 2012 97 4507-4514. (doi:10.1210/jc.2012-1808)
23. Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, Silverberg SJ & Bilezikian JP. Dynamic and structural properties of the skeleton in hypoparathyroidism. Journal of Bone and Mineral Research 2008 23 2018-2024. (doi:10.1359/jbmr.080803)
24. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C & Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. Journal of Clinical Endocrinology and Metabolism 2003 88 4214-4220. (doi:10.1210/jc.2002-021736)
25. Cooper MS. Disorders of calcium metabolism and parathyroid disease. Best Practice & Research. Clinical Endocrinology & Metabolism 2011 25 975-983. (doi:10.1016/j.beem.2011.07.001)
26. Kovacs CS & Kronenberg HM. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocrine Reviews 1997 18 832-872.
27. Kovacs CS & Fuleihan G. Calcium and bone disorders during pregnancy and lactation. Endocrinology and Metabolism Clinics of North America 2006 35 21-51, v. (doi:10.1016/j.ecl.2005.09.004)
28. Kovacs CS. Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones. Physiological Reviews 2014 94 1143-1218. (doi:10.1152/physrev. 00014.2014)
29. Mestman JH. Parathyroid disorders of pregnancy. Seminars in Perinatology 1998 22 485-496. (doi:10.1016/S0146-0005(98)80028-1)
30. Callies F, Arlt W, Scholz HJ, Reincke M & Allolio B. Management of hypoparathyroidism during pregnancy - report of twelve cases. European Journal of Endocrinology 1998 139 284-289. (doi:10.1530/eje.0.1390284)
31. Eastell R, Edmonds CJ, de Chayal RC & McFadyen IR. Prolonged hypoparathyroidism presenting eventually as second trimester abortion. BMJ 1985 291 955-956. (doi:10.1136/bmj.291.6500.955)
32. Krysiak R, Kobielusz-Gembala I & Okopien B. Hypoparathyroidism in pregnancy. Gynecological Endocrinology 2011 27 529-532. (doi:10. 3109/09513590.2010.507284)
33. Alikasifoglu A, Gonc EN, Yalcin E, Dogru D & Yordam N. Neonatal hyperparathyroidism due to maternal hypoparathyroidism and vitamin D deficiency: a cause of multiple bone fractures. Clinical Pediatrics 2005 44 267-269. (doi:10.1177/000992280504400312)
34. Demirel N, Aydin M, Zenciroglu A, Okumus N, Cetinkaya S, Yildiz YT & Ipek MS. Hyperparathyroidism secondary to maternal hypoparathyroidism and vitamin D deficiency: an uncommon cause of neonatal respiratory distress. Annals of Tropical Paediatrics 2009 29 149-154. (doi:10.1179/146532809X440770)
35. Landing BH & Kamoshita S. Congenital hyperparathyroidism secondary to maternal hypoparathyroidism. Journal of Pediatrics 1970 77 842-847. (doi:10.1016/S0022-3476(70)80245-1)
36. Loughead JL, Mughal Z, Mimouni F, Tsang RC & Oestreich AE. Spectrum and natural history of congenital hyperparathyroidism secondary to maternal hypocalcemia. American Journal of Perinatology 1990 7 350-355. (doi:10.1055/s-2007-999521)
37. Cooper MS & Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008 336 1298-1302. (doi:10.1136/bmj.39582.589433.BE)
38. Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, Jüppner H, D'Amour P, Fox J, Rejnmark L et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. Journal of Bone and Mineral Research 2011 26 2317-2337. (doi:10.1002/jbmr.483)
39. Porter RH, Cox BG, Heaney D, Hostetter TH, Stinebaugh BJ & Suki WN. Treatment of hypoparathyroid patients with chlorthalidone. New England Journal of Medicine 1978 298 577-581. (doi:10.1056/NEJM197803162981101)
40. Atkinson SA. The new dietary reference intakes from the Institute of Medicine for calcium and vitamin D. Perspective Infirmière: Revue Officielle de l'Ordre des Infirmières et Infirmiers du Québec 2011 8 5.
41. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. Journal of Clinical Endocrinology and Metabolism 2011 96 53-58. (doi:10.1210/jc.2010-2704)
42. Horwitz MJ & Stewart AF. Hypoparathyroidism: is it time for replacement therapy? Journal of Clinical Endocrinology and Metabolism 2008 93 3307-3309. (doi:10.1210/jc.2008-1216)
43. Winer KK, Sinaii N, Peterson D, Sainz B Jr & Cutler GB Jr. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 2008 93 3389-3395. (doi:10.1210/jc.2007-2552)
44. Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS & Cutler GB Jr. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 2012 97 391-399. (doi:10.1210/ jc.2011-1908)
45. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H et al. GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011 64 383-394. (doi:10.1016/j.jclinepi.2010. 04.026)
46. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schünemann HJ et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011 64 395-400. (doi:10.1016/j.jclinepi.2010. 09.012)
47. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011 64 401-406. (doi:10.1016/j.jclinepi.2010.07.015)
48. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology 2013 66 719-725. (doi:10.1016/j.jclinepi.2012.03.013)
49. Guyatt GH, Schunemann HJ, Djulbegovic B & Akl EA. Guideline panels should not GRADE good practice statements. Journal of Clinical Epidemiology 2015 68 597-600. (doi:10.1016/j.jclinepi.2014.12.011)
50. Arata RO, Mautalen CA, Geffner D & Horwith M. Effect of hydrochlorothiazide upon serum and urinary calcium in patients with hypoparathyroidism. Medicina 1974 34 463-470.
51. Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet. Diabetes & Endocrinology 2013 1 275-283. (doi:10.1016/S2213-8587(13)70106-2)
52. Cusano NE, Rubin MR, McMahon DJ, Irani D, Anderson L, Levy E & Bilezikian JP. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. Journal of Clinical Endocrinology and Metabolism 2014 99 3694-3699. (doi:10.1210/jc. 2014-2267)
53. Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L & Rejnmark L. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporosis International 2014 25 1717-1726. (doi:10.1007/s00198-014-2677-6)
54. Ong GS, Walsh JP, Stuckey BG, Brown SJ, Rossi E, Ng JL, Nguyen HH, Kent GN & Lim EM. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2012 97 3138-3145. (doi:10.1210/jc.2012-1429)
55. Kannan S, Mahadevan S, Velayutham P, Bharath R, Kumaravel V, Muthukumaran J & Premkumar A. Estimation of magnesium in patients with functional hypoparathyroidism. Indian Journal of Endocrinology and Metabolism 2014 18 821-825. (doi:10.4103/2230-8210.141365)
56. Thakker RV. Genetic developments in hypoparathyroidism. Lancet 2001 357 974-976. (doi:10.1016/S0140-6736(00)04254-9)
57. Rathod A, Bonny O, Guessous I, Suter PM, Conen D, Erne P, Binet I, Gabutti L, Gallino A, Muggli F et al. Association of urinary calcium excretion with serum calcium and vitamin D levels. Clinical Journal of the American Society of Nephrology 2015 10 452-462. (doi:10.2215/CJN. 12511213)
58. Coe FL, Evan A & Worcester E. Pathophysiology-based treatment of idiopathic calcium kidney stones. Clinical Journal of the American Society of Nephrology 2011 6 2083-2092. (doi:10.2215/CJN.11321210)
59. Caudarella R, Vescini F, Buffa A & Francucci CM. Hyperphosphatemia: effects on bone metabolism and cardiovascular risk. Journal of Endocrinological Investigation 2007 30 (6 Suppl) 29-34.
60. Rodriguez-Ortiz ME, Canalejo A, Herencia C, Martínez-Moreno JM, Peralta-Ramírez A, Perez-Martinez P, Navarro-González JF, Rodríguez M, Peter M, Gundlach K et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrology, Dialysis, Transplantation 2014 29 282-289. (doi:10.1093/ndt/gft400)
61. Autier P, Boniol M, Pizot C & Mullie P. Vitamin D status and ill health: a systematic review. Lancet. Diabetes & Endocrinology 2014 2 76-89. (doi:10.1016/S2213-8587(13)70165-7)
62. Aloia JF. Clinical Review: The 2011 report on dietary reference intake for vitamin D: where do we go from here? Journal of Clinical Endocrinology and Metabolism 2011 96 2987-2996. (doi:10.1210/jc.2011-0090)
63. Francis RM, Aspray TJ, Bowring CE, Fraser WD, Gittoes NJ, Javaid MK, Macdonald HM, Patel S, Selby PL & Tanna N. National Osteoporosis Society practical clinical guideline on vitamin D and bone health. Maturitas 2015 80 119-121. (doi:10.1016/j.maturitas.2014.11.018)
64. Hobaus J, Thiem U, Hummel DM & Kallay E. Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anti-Cancer Agents in Medicinal Chemistry 2013 13 20-35. (doi:10.2174/ 187152013804487434)
65. O'Seaghdha CM, Yang Q, Glazer NL, Leak TS, Dehghan A, Smith AV, Kao WH, Lohman K, Hwang SJ, Johnson AD et al. Common variants in the calcium-sensing receptor gene are associated with total serum calcium levels. Human Molecular Genetics 2010 19 4296-4303. (doi:10. 1093/hmg/ddq342)
66. Pearce S. Extracellular "calcistat" in health and disease. Lancet 1999 353 83-84. (doi:10.1016/S0140-6736(05)76148-1)
67. Davies M, Taylor CM, Hill LF & Stanbury SW. 1,25-Dihydroxycholecalciferol in hypoparathyroidism. Lancet 1977 1 55-59. (doi:10.1016/ S0140-6736(77)91077-7)
68. Hill LF, Davies M, Taylor CM & Standbury SW. Treatment of hypoparathyroidism with 1,25-dihydroxycholecalciferol. Clinical Endocrinology 1976 5 (Suppl) 167S-173S. (doi:10.1111/j.1365-2265. 1976.tb03824.x)
69. Kanis JA, Russell RG & Smith R. Physiological and therapeutic differences between vitamin D, its metabolites and analogues. Clinical Endocrinology 1977 7 (Suppl) 191s-201s. (doi:10.1111/j.1365-2265. 1977.tb03381.x)
70. Kanis JA & Russell RG. Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1a-hydroxylated derivatives. BMJ 1977 1 78-81. (doi:10.1136/bmj.1.6053.78)
71. Okano K, Furukawa Y, Morii H & Fujita T. Comparative efficacy of various vitamin D metabolites in the treatment of various types of hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 1982 55 238-243. (doi:10.1210/jcem-55-2-238)
72. Seino Y, Tanaka H, Yamaoka K & Yabuuchi H. Circulating 1α,25-dihydroxyvitamin D levels after a single dose of 1α,25-dihydroxyvitamin D3 or 1α-hydroxyvitamin D3 in normal men. Bone and Mineral 1987 2 479-485.
73. Recker RR & Heaney RP. The effect of milk supplements on calcium metabolism, bone metabolism and calcium balance. American Journal of Clinical Nutrition 1985 41 254-263.
74. Harvey JA, Zobitz MM & Pak CY. Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate. Journal of Bone and Mineral Research 1988 3 253-258. (doi:10.1002/ jbmr.5650030303)
75. Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutrition in Clinical Practice 2007 22 286-296. (doi:10.1177/0115426507022003286)
76. Zamfirescu I & Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid 2011 21 483-486. (doi:10.1089/thy.2010.0296)
77. Malberti F. Hyperphosphataemia: treatment options. Drugs 2013 73 673-688. (doi:10.1007/s40265-013-0054-y)
78. el-Hajj FG, Seifter J, Scott J & Brown EM. Calcium-regulated renal calcium handling in healthy men: relationship to sodium handling. Journal of Clinical Endocrinology and Metabolism 1998 83 2366-2372.
79. Karp HJ, Ketola ME & Lamberg-Allardt CJ. Acute effects of calcium carbonate, calcium citrate and potassium citrate on markers of calcium and bone metabolism in young women. British Journal of Nutrition 2009 102 1341-1347. (doi:10.1017/S0007114509990195)
80. Kurzel RB & Hagen GA. Use of thiazide diuretics to reduce the hypercalciuria of hypoparathyroidism during pregnancy. American Journal of Perinatology 1990 7 333-336. (doi:10.1055/s-2007-999516)
81. Newman GH, Wade M & Hosking DJ. Effect of bendrofluazide on calcium reabsorption in hypoparathyroidism. European Journal of Clinical Pharmacology 1984 27 41-46. (doi:10.1007/BF02395204)
82. Parfitt AM. Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism. Annals of Internal Medicine 1972 77 557-563. (doi:10.7326/0003-4819-77-4-557)
83. Santos F, Smith MJ & Chan JC. Hypercalciuria associated with longterm administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. American Journal of Diseases of Children 1986 140 139-142. (doi:10.1001/archpedi.1986.02140160057032)
84. Maschio G, Tessitore N, D'Angelo A, Fabris A, Pagano F, Tasca A, Graziani G, Aroldi A, Surian M, Colussi G et al. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol. American Journal of Medicine 1981 71 623-626. (doi:10.1016/0002-9343(81)90215-1)
85. Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F & Mosekilde L. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. European Journal of Clinical Investigation 2003 33 41-50. (doi:10.1046/j. 1365-2362.2003.01103.x)
86. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM et al. Medical management of kidney stones: AUA guideline. Journal of Urology 2014 192 316-324. (doi:10.1016/j.juro.2014.05.006)
87. Qaseem A, Dallas P, Forciea MA, Starkey M & Denberg TD. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2014 161 659-667. (doi:10. 7326/M13-2908)
88. Cannata-Andia JB & Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrology, Dialysis, Transplantation 2002 17 (Suppl 11) 16-19. (doi:10.1093/ndt/ 17.suppl-11.16)
89. Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, Shroff R, Thadhani RI, Tonelli MA, Kasiske BL et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney International 2015 87 502-528. (doi:10.1038/ki.2014.425)
90. Epstein M, McGrath S & Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. New England Journal of Medicine 2006 355 1834-1836. (doi:10.1056/NEJMc066308)
91. Lubi M, Tammiksaar K, Matjus S, Vasar E & Volke V. Magnesium supplementation does not affect blood calcium level in treated hypoparathyroid patients. Journal of Clinical Endocrinology and Metabolism 2012 97 E2090-E2092. (doi:10.1210/jc.2012-2301)
92. Fatemi S, Ryzen E, Flores J, Endres DB & Rude RK. Effect of experimental human magnesium depletion on parathyroid hormone secretion and 1,25-dihydroxyvitamin D metabolism. Journal of Clinical Endocrinology and Metabolism 1991 73 1067-1072. (doi:10.1210/jcem-73-5-1067)
93. Touliatos JS, Sebes JI, Hinton A, McCommon D, Karas JG & Palmieri GM. Hypoparathyroidism counteracts risk factors for osteoporosis. American Journal of Medical Sciences 1995 310 56-60. (doi:10.1097/00000441-199508000-00003)
94. Heath H III, Odelberg S, Jackson CE, Teh BT, Hayward N, Larsson C, Buist NR, Krapcho KJ, Hung BC, Capuano IV et al. Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. Journal of Clinical Endocrinology and Metabolism 1996 81 1312-1317. (doi:10.1210/jcem.81.4.8636323)
95. Lienhardt A, Bai M, Lagarde JP, Rigaud M, Zhang Z, Jiang Y, Kottler ML, Brown EM & Garabédian M. Activating mutations of the calcium-sensing receptor: management of hypocalcemia. Journal of Clinical Endocrinology and Metabolism 2001 86 5313-5323. (doi:10.1210/jcem.86.11.8016)
96. Sato K, Hasegawa Y, Nakae J, Nanao K, Takahashi I, Tajima T, Shinohara N & Fujieda K. Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. Journal of Clinical Endocrinology and Metabolism 2002 87 3068-3073. (doi:10.1210/jcem.87.7.8639)
97. Caplan RH & Beguin EA. Hypercalcemia in a calcitriol-treated hypoparathyroid woman during lactation. Obstetrics and Gynecology 1990 76 485-489.
98. Sadeghi-Nejad A, Wolfsdorf JI & Senior B. Hypoparathyroidism and pregnancy. Treatment with calcitriol. Journal of the American Medical Association 1980 243 254-255. (doi:10.1001/jama.1980. 03300290036018)
99. Salle BL, Berthezene F, Glorieux FH, Delvin EE, Berland M, David L, Varenne JP & Putet G. Hypoparathyroidism during pregnancy: treatment with calcitriol. Journal of Clinical Endocrinology and Metabolism 1981 52 810-813. (doi:10.1210/jcem-52-4-810)
100. Graham WP III, Gordan GS, Loken HF, Blum A & Halden A. Effect of pregnancy and of the menstrual cycle on hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 1964 24 512-516. (doi:10.1210/jcem-24-6-512)
101. Mather KJ, Chik CL & Corenblum B. Maintenance of serum calcium by parathyroid hormone-related peptide during lactation in a hypoparathyroid patient. Journal of Clinical Endocrinology and Metabolism 1999 84 424-427. (doi:10.1210/jcem.84.2.5486)
102. Cundy T, Haining SA, Guilland-Cumming DF, Butler J & Kanis JA. Remission of hypoparathyroidism during lactation: evidence for a physiological role for prolactin in the regulation of vitamin D metabolism. Clinical Endocrinology 1987 26 667-674. (doi:10.1111/ j.1365-2265.1987.tb00824.x)
103. Markestad T, Ulstein M, Bassoe HH, Aksnes L & Aarskog D. Vitamin D metabolism in normal and hypoparathyroid pregnancy and lactation. Case report. British Journal of Obstetrics and Gynaecology 1983 90 971-976. (doi:10.1111/j.1471-0528.1983.tb06774.x)
104. Rude RK, Haussler MR & Singer FR. Postpartum resolution of hypocalcemia in a lactating hypoparathyroid patient. Endocrinologia Japonica 1984 31 227-233. (doi:10.1507/endocrj1954.31.227)
105. Shomali ME & Ross DS. Hypercalcemia in a woman with hypoparathyroidism associated with increased parathyroid hormone-related protein during lactation. Endocrine Practice 1999 5 198-200. (doi:10.4158/EP.5.4.198)
106. Wright AD, Joplin GF & Dixon HG. Post-partum hypercalcaemia in treated hypoparathyroidism. BMJ 1969 1 23-25. (doi:10.1136/bmj.1. 5635.23)
107. Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A, Sliney J Jr, Cremers SC & Bilezikian JP. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. Journal of Clinical Endocrinology and Metabolism 2013 98 137-144. (doi:10.1210/jc.2012-2984)